Amgen Inc. (AMGN) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

My name is Julianne and I will be your conference facilitator today for the Amgen Q1 FY 2025 earnings conference call. All lines have been placed on mute to prevent any background noise. There will be a question and answer session at the conclusion of the last speaker's prepared remarks. In order to ensure that everyone has a chance to participate, we would like to request that you limit yourself to asking one question during the Q&A session. To ask a question, please press star then the number one on your telephone keypad. To withdraw your question, please press star 1 again. I would now like to introduce Justin Clays, Vice President of Investor Relations. Mr. Clays, you may now begin. Good afternoon, and welcome to our first quarter 2025 earnings call. Bob Bradley will lead the call and be followed by a broader review of our performance by Myrtle Gordon, Jay Bradner, and Peter Griffith. Through the course of our discussion today, we will use non-GAAP financial measures to describe our performance, and have provided appropriate reconciliations within the materials that accompany this call. We will also make some forward-looking statements, which are qualified by our Safe Harbor Statement, and please note that actual results can vary materially. Over to you, Bob. Okay, good afternoon, everyone, and thank you for joining us today. We're off to a strong start in 2025, and this was an exciting quarter, one with strong volume growth across the enterprise, important new product launches, and positive Phase III data. Revenue grew 9% year-over-year. Volume grew 14%, reflecting growing patient demand for our innovative medicines. Fourteen of our medicines delivered double-digit sales growth, spanning general medicine, rare disease, inflammation, and oncology. Our industry-le...